Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ōtsu
Clinical trial register · Japan

Clinical Trials in Ōtsu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC7 Novartis Pharmaceuticals4 Pfizer4 Sanofi3 Bristol-Myers Squibb3
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Ōtsu

50 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)
NCT07855692HFpEF - Heart Failure With Preserved Ejection Fraction
DrugTamibarotene
Nagoya University
Phase 2
90
Nagoya, Ōbu, Tsu, Tokyo
2026-10-01
Recruiting
Takeda
Phase 3
324
Chiba, Toon-shi, Kobe, Hitachi, Tsu, Miyazaki, Bunkyo-Ku, Chuo-shi
2026-09-10
Recruiting
Takeda
Phase 2
9
Nagoya, Maebashi, Tsu, Suita, Bunkyo-ku, Shinjuku-ku, Sumida-ku, Chūō
2026-07-14
Not yet open
Matthias Stuber
Observational
300
Tsu
2026-06
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Kamogawa, Sapporo, Kobe, Shiwa-Gun, Tsu, Bunkyo Ku, Bunkyo-ku, Chūō
2026-05-27
Recruiting
Genmab
Phase 3
544
Sapporo, Akashi, Tsu, Takatsuki, Hidaka, Kashiwa, Kawasaki, Kurume
2026-04-03
Active, closed
Intuitive Surgical
Observational
625
Ichinomiya, Toyoake, Yokohama, Kyoto, Tsu, Ageo, Tokyo
2026-03-26
Recruiting
Sanofi
Phase 3
751
Kamakura, Nishinomiya, Tsu
2026-01-22
Recruiting
Genmab
Phase 3
660
Chiba, Ōta, Shiwa-gun, Sagamihara-shi, Yokohama, Tsu, Sendai, Osaka
2025-11-28
Recruiting
Novartis Pharmaceuticals
Phase 3
31
Toyoake, Kurume, Ōtsu, Fuchū
2025-11-27
Recruiting
Pfizer
Phase 3
680
Kurume, Kure, Akashi, Kochi, Tsu, Sendai, Ōmura, Beppu-shi
2025-09-29
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Nagoya-sh, Toyoake Shi, Asahikawa-shi, Suita, Suita-shi, Ōtsu, Chūōku, Fukuoka
2025-09-22
Recruiting
Pfizer
Phase 3
714
Tōon, Kurume, Otashi, Asahikawa, Kobe, Yokohama, Tsu, Sendai
2025-07-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Matsuyama, Sapporo, Tsu, Hirakata, Sakai, Hidaka, Sunto-gun
2025-07-21
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Kamogawa, Matsuyama, Hiroshima, Morioka, Kamakura, Tsu, Miyazaki, Hirakata
2025-07-18
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Ōbu, Narashino, Kawasaki, Tsu, Kurashiki, Hirakata, Kanzaki-gun, Shinjuku
2025-07-16
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Nagoya, Matsuyama, Sapporo, Kahoku-gun, Yokohama, Tsu, Naha, Hirakata
2025-06-30
Recruiting
Pfizer
Phase 2
620
Kasugai, Matsudo, Sakura, Sapporo, Koga, Sagamihara, Yokohama, Tsu
2025-06-19
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Kashiwa, Sakura, Chikushino-shi, Maebashi, Shiwa-gun, Yokohama, Tsu, Sendai
2025-05-27
Recruiting
Takeda
Phase 3
59
Nagoya, Kumamoto, Sendai, Kashihara, Higashi-Matsuyama, Ōtsu, Tokushima, Bunkyo-ku
2025-05-06
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Fukuoka, Tsu, Kawagoe, Saitama, Hiroshima, Kawasaki, Nagasaki, Saga
2025-03-20
Recruiting
Novartis Pharmaceuticals
Observational
30
Ōbu, Toyoake, Kurume, Sapporo, Tsukuba, Kawasaki, Yokohama, Tsu
2024-12-19
Active, closed
JCR Pharmaceuticals Co., Ltd.
Phase 1/2
10
Hiroshima, Okinawa, Tokyo, Tsu
2024-11-05
Active, closed
Verastem, Inc.
Phase 2
16
Nagoya, Kurume, Tsu, Sendai, Minato
2024-10-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Toyoake, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai, Hirakata
2024-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Kashiwa, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama, Tsu
2024-04-14
Recruiting
Verastem, Inc.
Phase 3
270
Tsu, Aichi, Miyagi, Osaka, Tokyo
2024-03-18
Recruiting
Yonsei University
Phase 2
198
Kurume, Fukushima, Tsu, Sendai, Niigata, Hidaka, Tokushima, Tokyo
2024-01-22
By invitation
Sanofi
Phase 3
90
Isehara, Tsu, Ureshino, Fukuoka
2024-01-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Toyoake, Kashiwa, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai
2023-12-31
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Kitakyushu, Sapporo, Kamimashi-gun, Habikino, Takatsuki, Ōtsu, Izumo, Bunkyo-ku
2023-12-07
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Itabashi Ku, Kitakyushu-shi, Mito, Nagoya, Osaka Sayama Shi, Sendai, Shinjuku, Tsu
2023-10-12
Active, closed
Incyte Corporation
Phase 1
160
Chiba-ken, Kagoshima, Osaka, Tokyo, Tsu
2023-09-25
Recruiting
Management and Outcomes of Local Complications of Acute Pancreatitis and Postoperative Pancreatic Fistula
NCT07862088Acute Pancreatitis, Pancreatic Fluid Collection, Postoperative Pancreatic Fistula
Tokyo University
Observational
5,000
Ōtsu, Bunkyō-Ku, Tokyo, Gifu, Hyōgo, Kawagoe, Kobe, Ōsaka-sayama
2023-09-14
Recruiting
AstraZeneca
Phase 3
231
Fukuoka, Fukuyama, Funabashi-shi, Nara, Odawara, Ōtsu, Saga, Shimotsuga-gun
2023-08-24
Active, closed
AbbVie
Phase 3
1,328
Fukuoka, Nishinomiya-shi, Tsukuba, Kyoto, Sendai, Ginowan-shi, Sakai-shi, Ōtsu
2023-06-21
Recruiting
Pfizer
Phase 3
318
Kitakyushu-shi, Kawasaki, Sendai, Okayama, Ōtsu, Bunkyo-ku, Shinjuku-ku, Ube
2023-05-20
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Shinjuku-ku, Fukuoka, Itabashi-ku, Kumamoto, Mitaka, Miyazaki, Sendai, Tsu
2022-06-30
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Sapporo, Isehara, Tsu, Hirakata, Bunkyo, Minato, Chūō, Fukuoka
2022-01-14
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Nagoya, Fukushima, Kobe, Nishinomiya-shi, Kagoshima, Kyoto, Miyazaki, Ōtsu
2022-01-13
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Bunkyō City, Gunma, Ikoma, Kurume, Saitama Shi, Sendai, Setagaya Ku, Tsu
2021-10-18
Active, closed
AbbVie
Phase 3
132
Nagoya, Tsu, Hirakata-shi, Shinjuku-ku
2021-07-24
Active, closed
Bristol-Myers Squibb
Phase 3
729
Nagoya, Sapporo, Tsu, Kawachi-Nagano, Bunkyō, Chuo-ku, Itabashi-ku, Meguro-ku
2021-07-15
Recruiting
Bristol-Myers Squibb
Phase 3
153
Nagoya, Fukuoka, Jonan-Ku, Isehara, Tsu, Itabashi-ku, Shinjuku-ku, Osaka
2021-03-23
Recruiting
PharmaEssentia Japan K.K.
Phase 3
67
Toon-shi, Tsu, Suita-shi, Bunkyo-ku, Shinjuku-ku, Chuo-shi
2021-01-19
Active, closed
PharmaEssentia
Phase 3
174
Tōon, Sagamihara, Tsu, Miyazaki, Hirakata, Sayama, Suita, Izunokuni
2020-08-25
Active, closed
Sanofi
Observational
1,860
Sagamihara, Yokohama, Tsu, Habikino, Fuchū, Fukuoka, Fukuyama-shi, Hiroshima
2019-08-15
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Chūō, Fukuoka, Fukushima, Miyagi, Miyazaki, Tokyo, Tōon, Tsu
2017-06-26
Active, closed
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03155191Lymphoblastic Leukemia, Acute Adult
Takara Bio Inc.
Phase 1/2
21
Akita, Yoshida, Higashiku, Sapporo, Kobe, Tsu, Sendai, Okayama
2017-06-01
Recruiting
Manuel Monreal
Observational
120,000
Kitakyushu, Maebashi, Amagasaki, Kumamoto, Kyoto, Tsu, Nagasaki, Osaka
2001-03
Rows per page Showing 1–50 of 50
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/tsu

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 50 of those studies with a site in Ōtsu.

How many clinical trials are recruiting in Ōtsu?

27 of the 50 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 2 have not yet opened recruitment, 20 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ōtsu), 50 studies
PhaseStudiesRecruitingShare
Phase 3331866%
Phase 27514%
Observational6312%
Phase 1/2204%
Phase 1102%
Phase 2/3112%

Most active sponsors

Lead sponsors with the most studies (Ōtsu)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC75
Novartis Pharmaceuticals43
Pfizer44
AbbVie30
Bristol-Myers Squibb32
Sanofi31
Takeda33
Genmab22
Janssen Research & Development, LLC20
PharmaEssentia20
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.